Dergoing Transrectal Ultrasound (TRUS) guided prostate biopsy. Abbreviations AS: Active surveillance; EAU: European Association of

Dergoing Transrectal Ultrasound (TRUS) guided prostate biopsy. Abbreviations AS: Active surveillance; EAU: European Association of Urology; HRQOL: Wellness related top quality of life; MRI: Magnetic resonance imaging; PCa: Prostate Cancer; PIL: Patient details leaflet; ProBE: Prostate Biopsy Effects study; Guard: Prostate testing for cancer and Therapy trial, International Typical Randomised Controlled Trial Quantity 20141297; PSA: ProstateWade et al. BMC Overall health Services Investigation (2015) 15:Page 9 ofspecific antigen; RCT: Randomised controlled trial; RP: Radical prostatectomy; TRUS-Bx: Transrectal ultrasound guided biopsy. Competing interests The authors declare they’ve read and understood the BMC Health Solutions Research policy on declarations of interest and have no interests to declare. Authors’ contributions JW and JLD conceived the study and had been mainly responsible for the evaluation plus the completed manuscript. JW, JD, KNLA and CES conducted interviews and contributed to evaluation; DJR, JLD, JAL, and FCH devised the ProBE study protocol and arranged integration into the ongoing Safeguard study. Guard study funding was obtained by FCH, DEN and JLD. CM offered statistical experience within ProBE, contributed to data analysis and interpretation and with each other with DJR, JAL and JH contributed to improvement on the revised patient HIV-1 Species information. MLG contributed to study design and acted as nurse consultant in ProBE. KNLA and JMB carried out the preliminary qualitative study that highlighted locations of concern and contributed to the ProBE study style. DEN advised on investigation priorities inside ProBE, advised on integration into the ongoing Defend study, and contributed to study design and style. All authors critically revised the manuscript and revised it for vital intellectual content. JW will be the guarantor. All authors read and approved the final manuscript. Acknowledgements The authors acknowledge the tremendous contributions for the ProBE (Prostate Biopsy Effects) Study Group of Prasad Bollina, Sue Bonnington, Lynn Bradshaw, Debbie Cooper, Liz Down, Alan Doherty, Garrett Durkan, Emma Elliott, David Gillatt, Pippa Herbert, Peter Holding, Mandy Jones, Roger Kockelbergh, Howard Kynaston, Teresa Lennon, Norma Lyons, Hing Leung, Malcolm Mason, Hilary Moody, James N’Dow, Philip Powell, Alan Paul, Stephen Prescott, Patricia O’Sullivan, Pauline Thompson, and Sarah Tidball; and moreover for the Guard study group of James Catto, Michael Davis, Andrew Doble. The ProBE study was funded by the UK Prostate Cancer Threat Management Group. The Safeguard study is funded by the UK National Institute for Health Research Wellness Technology Assessment (NIHR HTA) Programme (Projects No. 96/20/ 06, 96/20/99) and will be published in full in Well being Technology Assessment. JLD, FCH and DEN are NIHR senior investigators. The Top quality of Life in Guard study was funded by Cancer Investigation UK. The views and opinions expressed are those on the authors and usually do not necessarily reflect those with the HTA programme, NIHR, Cancer Study UK, the NHS or the Division of Health. Author Leukotriene Receptor Gene ID specifics 1 School of Social and Community Medicine, University of Bristol, 39 Whatley Road, Clifton, Bristol BS8 2PS, UK. 2Academic Urology Unit, Royal Hallamshire Hospital, University of Sheffield, Sheffield S10 2JF, UK. 3Protect study Urology Research, Royal Hallamshire Hospital, Sheffield S10 2JF, UK. 4Oncology Centre, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK. five Nuffield Departme.